Idactamab INT-001 represents a exciting clinical method for combating selected oncological malignancies. The immunoglobulin is a distinct mechanism of action, particularly interacting with the CD38 antigen, a https://deaconoezx599826.wikipresses.com/7350674/idacta_mab_int_001_a_innovative_antigen_binding_protein_under_progression